Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BBOpCo: Botensilimab and Balstilimab in Colorectal Cancer
NCT06268015Phase 2Active, not recruiting
- Sponsor
- Nicholas DeVito
- Start
- Nov 2024
- Primary completion
- Jul 2028
- Modality
- Monoclonal Antibodies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botensilimab and balstilimab in colorectal cancer (CRC), sponsored by Nicholas DeVito. Primary endpoints: Disease Control Rate based on iRECIST at 24 weeks and Objective Response Rate based on iRECIST up to 2 years. Started Nov 2024; status: active, not recruiting.
02
Drugs
botensilimabbalstilimab
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06268015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06268015.